Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07781891
PHASE2
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
Sponsor: M.D. Anderson Cancer Center
View on ClinicalTrials.gov
Summary
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
Official title: Rapid Advancement Of Promising Innovative Drugs (RAPID): A Patient-Centric, Investigator-Initiated, Bayesian, Multi-Center, Open-Label, Phase 2 Platform Trial Of Promising Drugs For AYA Patients With Relapsed/Refractory Ewing Sarcoma & DSRCT
Key Details
Gender
All
Age Range
10 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2027-02-01
Completion Date
2033-06-30
Last Updated
2026-08-24
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
LX-101
Given by injection
Locations (1)
MD Anderson Cancer Center
Houston, Texas, United States